[1]谢祯晖,陈长源.老年退行性心脏瓣膜病的流行病学现状及
诊疗进展[J].国际心血管病杂志,2023,02:65-68.
点击复制
老年退行性心脏瓣膜病的流行病学现状及
诊疗进展(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2023年02期
- 页码:
- 65-68
- 栏目:
- 综述
- 出版日期:
- 2023-03-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2023.02.001
- 文献标识码:
- -
- 摘要:
- 近20 年来，全球老年退行性心脏瓣膜病（SDHVD）的发病率、死亡率与患病 人数不断升高。随着人口老龄化的加剧，SDHVD 已逐渐成为我国重要的公共卫生问题。国 内外心脏瓣膜病的流行病学变化以及近年来放射影像学与核医学的进展为SDHVD 的早期 诊断与进展评估提供了更为准确的依据，经导管生物瓣膜植入术的推广为SDHVD 提供了新 的治疗方案。
- Abstract:
- -
参考文献/References
[1] Pomerance A. Ageing changes in human heart valves[J]. Br
Heart J, 1967, 29(2):222-231.
[2] Chen J, Li WD, Xiang MX. Burden of valvular heart disease,
1990—2017: results from the Global Burden of Disease Study
2017[J]. J Glob Health, 2020, 10(2):020404.
[3] Yadgir S, Johnson CO, Aboyans V, et al. Correction to:
global, regional, and national burden of calcific aortic valve
and degenerative mitral valve diseases, 1990—2017[J].
Circulation, 2020, 141(21):1670-1680.
[4] Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic
valve disease: not simply a degenerative process: a review
and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive
summary: calcific aortic valve disease—2011 update[J].
Circulation, 2011, 124(16):1783-1791.
[5] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS
guidelines for the management of valvular heart disease[J].
Eur J Cardiothorac Surg, 2021, 60(4):727-800.
[6] Timmis A, Vardas P, Townsend N, et al. European society of
cardiology: cardiovascular disease statistics 2021[J]. Eur Heart
J, 2022, 43(8):716-799.
[7] Watkins DA, Johnson CO, Colquhoun SM, et al. Global,
regional, and national burden of rheumatic heart disease,
1990—2015[J]. N Engl J Med, 2017, 377(8):713-722.
[8] 叶蕴青, 许海燕, 李喆, 等. 中国不同区域老年瓣膜性心脏
病构成和病因分析[J]. 中华老年心脑血管病杂志, 2019,
21(7):676-682．
[9] Yang Y, Wang ZW, Chen Z, et al. Current status and etiology
of valvular heart disease in China: a population-based
survey[J]. BMC Cardiovasc Disord, 2021, 21(1):339.
[10] D'Arcy JL, Coffey S, Loudon MA, et al. Large-scale
community echocardiographic screening reveals a major
burden of undiagnosed valvular heart disease in older people:
the OxVALVE Population Cohort Study[J]. Eur Heart J, 2016,
37(47):3515-3522.
[11] Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA
guideline for the management of patients with valvular heart
disease: a report of the American College of Cardiology/
American Heart Association Joint Committee on Clinical
Practice Guidelines[J]. Circulation, 2021, 143(5):e72-e227.
[12] Doris MK, Jenkins W, Robson P, et al. Computed tomography
aortic valve calcium scoring for the assessment of aortic
stenosis progression[J]. Heart, 2020, 106(24):1906-1913.
[13] Dweck MR, Jenkins WSA, Vesey AT, et al. 18F-sodium
fluoride uptake is a marker of active calcification and disease
progression in patients with aortic stenosis[J]. Circ Cardiovasc
Imaging, 2014, 7(2):371-378.
[14] Pawade TA, Doris MK, Bing R, et al. Effect of denosumab
or alendronic acid on the progression of aortic stenosis: a
double-blind randomized controlled trial[J]. Circulation, 2021,
143(25):2418-2427.
[15] Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical
aortic-valve replacement in intermediate-risk patients[J]. N
Engl J Med, 2016, 374(17):1609-1620.
[16] Pibarot P, Salaun E, Dahou A, et al. Echocardiographic results
of transcatheter versus surgical aortic valve replacement in
low-risk patients: the PARTNER 3 trial[J]. Circulation, 2020,
141(19):1527-1537.
[17] S?ndergaard L, Ihlemann N, Capodanno D, et al. Durability
of transcatheter and surgical bioprosthetic aortic valves in
patients at lower surgical risk[J]. J Am Coll Cardiol, 2019,
73(5):546-553.
[18] Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration
of transcatheter versus surgical aortic valve bioprostheses
in the PARTNER-2 trial[J]. J Am Coll Cardiol, 2020,
76(16):1830-1843.
[19] Feldman T, Kar S, Elmariah S, et al. Randomized comparison
of percutaneous repair and surgery for mitral regurgitation:
5-year results of EVEREST Ⅱ[J]. J Am Coll Cardiol, 2015,
66(25):2844-2854.
[20] Guerrero M, Wang DD, Eleid MF, et al. Prospective study of
TMVR using balloon-expandable aortic transcatheter valves
in Mac: MITRAL trial 1-year outcomes[J]. JACC Cardiovasc
Interv, 2021, 14(8):830-845.
[21] Masri A, Svensson LG, Griffin BP, et al. Contemporary natural
history of bicuspid aortic valve disease: a systematic review[J].
Heart, 2017, 103(17):1323-1330.
[22] Hirji SA, Percy ED, McGurk S, et a l . Incidence,
characteristics, predictors, and outcomes of surgical
explantation after transcatheter aortic valve replacement[J]. J
Am Coll Cardiol, 2020, 76(16):1848-1859.
[23] Tam DY, Dharma C, Rocha RV, et al. Transcatheter ViV versus
redo surgical AVR for the management of failed biological
prosthesis: early and late outcomes in a propensity-aatched
cohort[J]. JACC Cardiovasc Interv, 2020, 13(6):765-774.
备注/Memo
- 备注/Memo:
- 通信作者：陈长源， E-mail：chenchangyuan.75@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1
- 全文下载/Downloads442
- 评论/Comments
